ZVRA vs RARE vs FOLD vs IONS vs BEAM

For growth investors, Zevra Therapeutics, Inc.

(ZVRA) is the stronger pick with 350. 9% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Zevra Therapeutics, Inc. (ZVRA) offers the better valuation at 8. 1x trailing P/E (22. 6x forward), making it the more compelling value choice. Analysts rate Zevra Therapeutics, Inc. (ZVRA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Zevra Therapeutics, Inc.

is actually cheaper at 22. 6x.

Over the past 5 years, Ionis Pharmaceuticals, Inc.

(IONS) delivered a total return of +108. 0%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: IONS returned +121. 1% versus ZVRA's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 55β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 293% more volatile than IONS relative to the S&P 500. On balance sheet safety, Beam Therapeutics Inc. (BEAM) carries a lower debt/equity ratio of 24% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zevra Therapeutics, Inc.

(ZVRA) is pulling ahead at 350. 9% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: Zevra Therapeutics, Inc. grew EPS 159. 2% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ZVRA leads at 118. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zevra Therapeutics, Inc.

(ZVRA) is the more profitable company, earning 78. 2% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 78. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zevra Therapeutics, Inc.

(ZVRA) trades at 22. 6x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 18. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZVRA: 120. 5% to $24. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), +121. 1% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IONS: +121. 1%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.